R. E. Marcus
-
- Lymphoma Diagnosis and Treatment 10
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 7
- Hematology top 2%
- Hematopoietic Stem Cell Transplantation 13
- Acute Myeloid Leukemia Research 10
- Multiple Myeloma Research and Treatments 5
- Chronic Myeloid Leukemia Treatments 4
- Oncology top 5%
- Neutropenia and Cancer Infections 7
- Viral-associated cancers and disorders 5
- Reproductive Medicine top 5%
R. E. Marcus
45 papers receiving 1.8k citations
Hit Papers
Peers
Comparison fields: 5 of 84
- Pathology and Forensic Medicine 1.1k
- Genetics 640
- Hematology 514
- Oncology 979
- Reproductive Medicine 142
Countries citing papers authored by R. E. Marcus
This map shows the geographic impact of R. E. Marcus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. E. Marcus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. E. Marcus more than expected).
Fields of papers citing papers by R. E. Marcus
This network shows the impact of papers produced by R. E. Marcus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. E. Marcus. The network helps show where R. E. Marcus may publish in the future.
Co-authorship network
The 25 scholars most cited alongside R. E. Marcus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | Immunochemotherapy With Obinutuzumab Or Rituximab In Previously Untreated Follicular Lymphoma In The Randomized Phase III Gallium Study: Analysis By Chemotherapy Regimen | 2017 | 1 |
| 3 | 2009 | 14 | |
| 4 | 2008 | 0 | |
| 5 | 2006 | 7 | |
| 6 | 2004 | 40 | |
| 7 | 2003 | 4 | |
| 8 | 2001 | 99 | |
| 9 | 1998 | 31 | |
| 10 | 1998 | 49 | |
| 11 | High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients. | 1996 | 9 |
| 12 | 1996 | 1 | |
| 13 | 1996 | 11 | |
| 14 | 1996 | 9 | |
| 15 | 1996 | 33 | |
| 16 | 1995 | 6 | |
| 17 | 1994 | 2 | |
| 18 | 1994 | 14 | |
| 19 | 1993 | 10 | |
| 20 | 1991 | 1 |
About R. E. Marcus
R. E. Marcus is a scholar working on Hematology, Genetics and Oncology, having authored 47 papers that have together received 1.9k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (13 papers), Acute Myeloid Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (7 papers), Neutropenia and Cancer Infections (7 papers), Multiple Myeloma Research and Treatments (5 papers), Viral-associated cancers and disorders (5 papers) and Chronic Myeloid Leukemia Treatments (4 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.1k citations), Genetics (640 citations) and Hematology (514 citations). R. E. Marcus has collaborated with scholars based in United Kingdom, Switzerland and United States. Frequent co-authors include DC Linch, KA MacLennan, A.M. Jelliffe, G. Vaughan Hudson, B. W. Hancock, KM Ardeshna, AJ Norton, Peter Smith, Peter Hoskin and G. Bass. Their work appears in journals such as Bone Marrow Transplantation, British Journal of Haematology, Blood, Journal of Clinical Oncology and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.